Figure 1

Turmeric-derived nanoparticles (TDNPs 2) are isolated through sucrose gradient ultracentrifugation and administered orally to target inflamed colonic tissue in a murine colitis model. The schematic outlines the isolation workflow from edible turmeric to purified nanovesicles.

Figure 2

Characterization of turmeric-derived nanoparticles reveals two distinct bands (TDNPs 1 and TDNPs 2) at the 8%/30% and 30%/45% sucrose gradient interfaces, respectively. TDNPs 2 demonstrate appropriate size distribution and surface charge for oral drug delivery applications.

Figure 3

In vitro assessment of turmeric-derived nanovesicles demonstrates anti-inflammatory activity, including suppression of pro-inflammatory cytokine production in activated macrophages. Dose-dependent reductions in TNF-alpha and IL-6 secretion are observed.

Figure 4

Biodistribution imaging using IVIS Spectrum reveals that TDNPs 2 preferentially accumulate in inflamed colonic tissue following oral administration. Fluorescence signals are minimal in non-target organs including heart, liver, spleen, lung, and kidney.

Figure 5

Oral TDNPs 2 administration significantly attenuates disease activity index scores and colon shortening in DSS-induced colitis mice. Body weight recovery is also improved compared to untreated colitis controls.

Figure 6

Intestinal permeability assessment indicates that TDNPs 2 treatment preserves gut barrier integrity in colitis mice. Tight junction protein expression, including ZO-1 and occludin, is maintained at near-normal levels.